Maine Committee Advances Bill Overhauling Employer Drug Testing Rules, Including Cannabis Protections
- The Maine Labor Committee approved House Bill 2110, aimed at updating employer substance use testing laws with new protections for legal marijuana use.
- The bill recognizes legal cannabis use under Maine law as a legitimate medical explanation for positive drug tests, preventing automatic workplace penalties if properly justified.
- It introduces stricter workplace testing standards, requiring observable signs of impairment for “reasonable suspicion” testing and mandates medical review officers to handle positive results before employer notification.
- The legislation shortens the rehabilitation period after positive tests, standardizes testing protocols for federally and non-federally mandated employees, and enhances testing procedures and laboratory standards.
A Maine legislative committee has approved a bill that would significantly update the state’s employer substance use testing laws, including new protections tied to legal marijuana use.
The Legislature’s Labor Committee voted March 31 to advance House Bill 2110, sending the proposal forward with amendments after a work session earlier in the day. The measure, sponsored by State Representative Charles Skold (D), makes wide-ranging changes to how employers conduct and administer drug testing programs.
At its core, the bill clarifies that a “legitimate medical explanation” for a positive test includes the legal use of cannabis under Maine law, meaning certain marijuana use could no longer automatically result in workplace penalties if properly justified.
The legislation also requires that all confirmed positive drug test results be reviewed and reported by a medical review officer, rather than being sent directly to employers. Employees and applicants would be given a formal opportunity to contest non-negative test results and provide a medical explanation before any final determination is made.
Another key change involves workplace testing standards. The bill tightens definitions around “reasonable suspicion,” requiring observable signs of impairment rather than relying on anonymous tips or off-duty conduct alone. It also establishes clearer rules for random and “criteria-based” testing, replacing older terminology and ensuring selection methods are neutral and consistent.
Under the amended version, employers subject to federal drug testing requirements would need to apply those same standards to employees who are not federally mandated to be tested, creating a more uniform system across workplaces.
The proposal also modifies employee protections following a positive test. It shortens the required rehabilitation period from six months to 12 weeks while shifting the cost burden to the employee, and it maintains a pathway for workers to return to their jobs after completing treatment.
Additional provisions expand testing procedures, including allowing employees in certain situations to request blood testing for substances such as cannabis metabolites, and requiring laboratories to meet strict certification and quality control standards.